Amivantamab (Rybrevant)

Canada’s Drug Agency (CDA-AMC) recommends that Rybrevant in combination with carboplatin and pemetrexed be reimbursed by public drug plans for the treatment of adult patients with locally advanced (not amenable to curative therapies) or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after osimertinib, if certain conditions are met. Rybrevant should only be covered to treat patients aged 18 years or older with tumours harbouring EGFR exon 19 deletions or exon 21 L858R substitution mutations that have returned while on or after treatment with osimertinib, who are in relatively good health and have no active interstitial lung disease or unstable brain metastases. Rybrevant should only be reimbursed if it is prescribed by clinicians with expertise in treating NSCLC and its price is reduced.